11 results
The aim of this study is to determine safety, patency of placement and long term symptom-free outcome of a covered self expandable metal stent in patients with a benign CBD stricture.
The primary objective is to assess the safety and operation of the Stentys coronary stent system in patients with acute myocardial infarction compared with a balloon-expanding stent. These are the effect and safety in the short term (the procedure…
To determine the safety and effectiveness of Boston Scientific*s Everolimus-eluting coronary stent system (PROMUS Element*) for coronary revascularization in an unrestricted population compared to the Xience* Prime control.
The aim of this study is to determine safety, patency of placement and long term symptom-free outcome of a covered self expandable metal stent in patients with a benign CBD stricture.
The primary aim of the proposed study is to assess whether stenting for symptomatic vertebral artery stenosis >= 50% is feasible and safe. A secondary aim is to assess the rate of new vascular events in the territory of the vertebrobasilar…
To define indications for recently developed, but more expensive, self-expanding metal stents (SEMS) versus cheaper plastic stents in patients with primary or recurrent inoperable malignant extrahepatic common bile duct (CBD) obstruction, based on…
Primary:*To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegalySecondary:*To investigate the safety and tolerability of a single dose of lanreotide PRF…
The objective for the study is to establish a proof of concept for the use of self-expandable stenting in subacute to chronic total occlusions and evaluate the safety and effectiveness of the STENTYS Coronary Stent System in the treatment of these…
Primary Objective* To describe the antitumour efficacy of LAN monotherapy plus BSC every 28 days, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,…
Primary objective: To evaluate the effect of navitoclax in combination with ruxolitinib on splenomegaly response when compared to ruxolitinib in subjects with myelofibrosis.Secondary objectives:• To evaluate the effect of navitoclax in combination…
Primary Objective• To assess superiority of treatment with CAM2029 compared to treatment with octreotide long-acting release (LAR) or lanreotide autogel (ATG) on progression-free survival (PFS) in patients with unresectable/metastatic and well-…